Join our daily newsletter At The Bell to receive exclusive market insights
- AI-based diagnostic imaging company Artrya (AYA) signs its first US hospital clinical partnership with Huntsville Heart Center in Alabama
- The study will be conducted by Heart Center Research, a division of Huntsville Heart Center, to determine the efficacy of Artrya’s technology
- The study will use Artrya’s Salix Coronary Anatomy technology to report a unique combination of coronary disease biomarkers including components of high-risk plaque
- Artrya has also announced that the CEO from 2006 to 2012 of the American College of Cardiology in the United States Dr John Lewin has joined its Clinical Advisory Board
- Artrya ends the day in the grey with shares trading at 70 cents
AI-based diagnostic imaging company Artrya (AYA) has signed its first US hospital clinical partnership with Huntsville Heart Center in Alabama.
The study will be conducted by Heart Center Research, a division of Huntsville Heart Center, to determine the efficacy of Artrya’s technology.
The study will use Artrya’s Salix Coronary Anatomy technology to report a unique combination of coronary disease biomarkers including components of high-risk plaque.
“This is the company’s first clinical partnership in the US, and we are pleased that such a well-regarded heart centre has joined in our mission to create better detection of the world’s leading killer — heart disease,” Artrya USA Co-CEO’s Jory Tremblay and Ted Schwab commented.
“This clinical trial should be completed by October this year and provide validation of the technology and pave the way for its commercial use in the US.”
Artrya has also announced that the CEO from 2006 to 2012 of the American College of Cardiology in the United States Dr John Lewin has joined its Clinical Advisory Board.
Artrya has ended the day in the grey with shares trading at 70 cents.
